 MINNEAPOLIS, MN ACCESSWIRE April 23, 2020 Celcuity Inc. CELC, a functional cellular analysis company that is developing companion diagnostic tests designed to expand the eligible patient populations for targeted therapies, announced that it will release its financial results for the first quarter 2020 after the stock market close on Thursday, May 7, 2020. Our proprietary CELsignia diagnostic platform is currently the only commercially ready technology that we are aware of that uses a patients living tumor cells to identify the cellular activity that may be driving a patients cancer. 